Can-Fite BioPharma Ltd. (CANF)
3.35
+0.02
(+0.60%)
USD |
NYAM |
Aug 24, 16:00
3.47
+0.12
(+3.58%)
After-Hours: 04:09
Can-Fite BioPharma Enterprise Value : -4.492M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | -4.492M |
| August 21, 2026 | -4.518M |
| August 20, 2026 | -4.492M |
| August 19, 2026 | -4.322M |
| August 18, 2026 | -4.361M |
| August 17, 2026 | -4.190M |
| August 14, 2026 | -4.426M |
| August 13, 2026 | -4.426M |
| August 12, 2026 | -4.374M |
| August 11, 2026 | -4.544M |
| August 10, 2026 | -4.675M |
| August 07, 2026 | -4.374M |
| August 06, 2026 | -4.217M |
| August 05, 2026 | -4.688M |
| August 04, 2026 | -4.702M |
| August 03, 2026 | -4.728M |
| July 31, 2026 | -4.754M |
| July 30, 2026 | -4.584M |
| July 29, 2026 | -4.688M |
| July 28, 2026 | -4.741M |
| July 27, 2026 | -4.754M |
| July 24, 2026 | -4.702M |
| July 23, 2026 | -4.649M |
| July 22, 2026 | -4.557M |
| July 21, 2026 | -4.452M |
| Date | Value |
|---|---|
| July 20, 2026 | -4.544M |
| July 17, 2026 | -4.426M |
| July 16, 2026 | -4.531M |
| July 15, 2026 | -4.584M |
| July 14, 2026 | -4.662M |
| July 13, 2026 | -4.610M |
| July 10, 2026 | -4.623M |
| July 09, 2026 | -4.597M |
| July 08, 2026 | -4.623M |
| July 07, 2026 | -4.322M |
| July 06, 2026 | -3.902M |
| July 02, 2026 | -3.758M |
| July 01, 2026 | -2.814M |
| June 30, 2026 | -4.990M |
| June 29, 2026 | -5.055M |
| June 26, 2026 | -5.278M |
| June 25, 2026 | -5.029M |
| June 24, 2026 | -4.964M |
| June 23, 2026 | -4.885M |
| June 22, 2026 | -4.872M |
| June 18, 2026 | -4.977M |
| June 17, 2026 | -4.911M |
| June 16, 2026 | -4.950M |
| June 15, 2026 | -4.964M |
| June 12, 2026 | -5.160M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| BioLineRx Ltd. | 8.933M |
| XTL Biopharmaceuticals Ltd. | -- |
| Kamada Ltd. | 428.03M |
| Galmed Pharmaceuticals Ltd. | -12.23M |
| Revium Recovery, Inc. | -- |
Enterprise Value Related Metrics
| Earnings Yield | -371.6% |
| Normalized Earnings Yield | -371.44 |